Pharmaceutical & Biotech Lifecycle Management (I) - Are Generic´s Launching Earlier Than Ever?

Author:Mr Duncan Bucknell
Profession:Duncan Bucknell
 
FREE EXCERPT

Copyright Duncan Bucknell

I recently put together a pilot study to test some views on the factors which affect success in the ongoing war between 'innovator' and 'generic' companies. In this, the first in a series of articles, I look at one of the interesting (but expected) outcomes from the study - that over time, generic companies have become better at getting on to the market earlier. To comment on this article, please go to the equivalent

blog post on my site. If you are reading the blog, then you can read the full article in the

article section of the site.

Background

The study looked at 15 of the globally top selling pharmaceutical products on the market today to identify possible trends which might explain, and potentially predict what can be done to affect the length of monopoly. Future articles will explore some of the other interesting findiings, and provide updates as more data and aspects of lifecycle management are analysed. (Raw patent filing data was supplied by the team at GenericsWeb.)

'Generics' seem to be launching earlier than in the past

In the graph which accompanies this article, the X axis shows the number of years of monopoly achieved by each of the drugs. The Y axis shows the number of years ago that the first Active Pharmaceutical Ingredient (API) or Composition of Matter (COM) patent was filed in relation to the product.

The bottom left of the graph shows the products in this study for which the composition of matter patent was filed more recently (17 to 20 years ago), and the top right shows the products for which the COM / API patent was filed the longest ago (31 years). The graph goes up to the right - the oldest products in this study received the longest periods of monopoly.

The implication here is clearly that if you discovered a drug 30 years ago, you would have been more likely to get a longer period of monopoly (23 years) than if you discovered it 20 years ago. Note that this is 23 years after marketing authorisation (which took on average 10-13 years in this study) - so 33 to 36 years after the priority date of the original composition of matter patent.

Why has this happened?

There are no doubt many reasons why this trend is apparent (and please let me know your thoughts). Here are some:

1 - The Hatch-Waxman legislation came into effect in 1984 - during the period of this study. This provided an enormous incentive for 'generic' companies to seek to launch as early as possible in the US, in return for...

To continue reading

REQUEST YOUR TRIAL